Chris Ryan

Data showed that treatment with talazoparib plus enzalutamide resulted in a 37% reduction in the risk of progression or death as assessed by blinded independent central review.

The application is supported by findings from a phase 1 trial and two phase 3 trials, SPOTLIGHT and LIGHTHOUSE.

Data showed that nivolumab followed by nivolumab/ipilimumab resulted in an overall response rate of 34%.

“These findings from the SPOTLIGHT study showed high inter-reader and intra-reader agreement for interpretation of 18F-rhPSMA-7.3 PET/CT scans in the setting of biochemical recurrence,” said Phillip Kuo, MD, PhD.

Compared with baseline conventional imaging, PET imaging with 18F-rhPSMA-7.3 frequently led to post-scan disease upstaging in men with prostate cancer recurrence, according to the latest data from the phase 3 SPOTLIGHT trial.

According to Dreicer, standard treatment in this setting for most patients should include androgen deprivation therapy (ADT) in combination with 1 or 2 other agents vs ADT therapy alone.

The addition of lenvatinib to pembrolizumab did not improve overall survival in patients with advanced urothelial carcinoma.